Long-term blood pressure variability, incidence of hypertension and changes in renal function in type 2 diabetes.
Journal
Journal of hypertension
ISSN: 1473-5598
Titre abrégé: J Hypertens
Pays: Netherlands
ID NLM: 8306882
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
11
7
2020
medline:
17
6
2021
entrez:
11
7
2020
Statut:
ppublish
Résumé
Long-term visit-to-visit SBP variability (VVV) predicts cerebro-cardiovascular and renal events in patients with hypertension. Whether VVV predicts hypertension and/or chronic kidney disease is currently unknown. We assessed the role of VVV on the development of hypertension and changes in renal function in patients with type 2 diabetes and normal blood pressure (NBP) in a real-life clinical setting. Clinical records from 8998 patients with type 2 diabetes, NBP, and normal estimated glomerular filtration rate (eGFR) were analyzed. VVV was measured by SD of the mean SBP recorded in at least four visits during 2 consecutive years before follow-up. Hypertension was defined as SBP at least 140 mmHg and DBP at least 90 mmHg or the presence of antihypertensive treatment. Renal function was defined as worsening of albuminuria status and/or a reduction in eGFR at least 30% from baseline. After a mean follow-up time of 3.5 ± 2.8 years, 3795 patients developed hypertension (12.1 per 100 person-years). An increase of 5 mmHg VVV was associated with a 19% (P < 0.0001) and a 5% (P = 0.008) independent increased risk of developing hypertension and worsening of albuminuria, respectively. We found no association between VVV and eGFR decrease from baseline. Patients with VVV in the upper quartile (>12.8 mmHg) showed a 50% increased risk of developing hypertension (P < 0.0001) and an almost 20% increased risk of worsening albuminuria (P = 0.004) as compared with those in the lower one (<6.9 mmHg). Increased VVV independently predicts incident hypertension and albuminuria worsening in type 2 diabetes and NBP.
Identifiants
pubmed: 32649633
doi: 10.1097/HJH.0000000000002543
pii: 00004872-202011000-00028
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2279-2286Références
Wu C, Shlipak MG, Stawski RS, Peralta CA, Psaty BM, Harris TB, et al. Health ABC StudyVisit-to-visit blood pressure variability and mortality and cardiovascular outcomes among older adults: the health, aging, and body composition study. Am J Hypertens 2017; 30:151–158.
Stevens SL, Wood S, Koshiaris C, Law K, Glasziou P, Stevens RJ, McManus RJ. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. BMJ 2016; 354:i4098.
Mehlum MH, Liestøl K, Kjeldsen SE, Julius S, Hua TA, Rothwell PM, et al. Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. Eur Heart J 2018; 39:2243–3225.
Chiriacò M, Pateras K, Virdis A, Charakida M, Kyriakopoulou D, Nannipieri M, et al. Association between blood pressure variability, cardiovascular disease and mortality in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2019; 21:2587–2598.
Gosmanova EO, Mikkelsen MK, Molnar MZ, Lu JL, Yessayan LT, Kalantar-Zadeh K, Kovesdy CP. Association of systolic blood pressure variability with mortality, coronary heart disease, stroke, and renal disease. J Am Coll Cardiol 2016; 68:1375–1386.
Whittle J, Lynch AI, Tanner RM, Simpson LM, Davis BR, Rahman M, et al. Visit-to-visit variability of BP and CKD outcomes: results of the ALLHAT. Clin J Am Soc Nephrol 2016; 11:471–480.
McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. Am J Kidney Dis 2014; 64:714–722.
Viazzi F, Bonino B, Mirijello A, Fioretto P, Giorda C, Ceriello A, et al. AMD-Annals Study GroupLong-term blood pressure variability and development of chronic kidney disease in type 2 diabetes. J Hypertens 2019; 37:805–813.
Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375:895–905.
De Cosmo S, Rossi MC, Pellegrini F, Lucisano G, Bacci S, Gentile S, et al. AMD-Annals Study GroupKidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. Nephrol Dial Transplant 2014; 29:657–662.
De Cosmo S, Viazzi F, Pacilli A, Giorda C, Ceriello A, Gentile S, et al. AMD-Annals Study GroupAchievement of therapeutic targets in patients with diabetes and chronic kidney disease: insights from the Associazione Medici Diabetologi Annals initiative. Nephrol Dial Transplant 2015; 30:1526–1533.
Viazzi F, Piscitelli P, Ceriello A, Fioretto P, Giorda C, Guida P, et al. AMD-Annals Study GroupResistant hypertension, time-updated blood pressure values and renal outcome in type 2 diabetes mellitus. J Am Heart Assoc 2017; 6:e006745.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). a new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604–612.
Levitan EB, Kaciroti N, Oparil S, Julius S, Muntner P. Relationships between metrics of visit-to-visit variability of blood pressure. J Hum Hypertens 2013; 27:589–593.
Stekhoven DJ, Bühlmann P. MissForest – nonparametric missing value imputation for mixed-type data. Bioinformatics 2012; 28:112–118.
Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol 2013; 10:143–155.
Muntner P, Joyce C, Levitan EB, Holt E, Shimbo D, Webber LS, et al. Reproducibility of visit-to-visit variability of blood pressure measured as part of routine clinical care. J Hypertens 2011; 29:2332–2338.
Weiss A, Beloosesky Y, Koren-Morag N, Grossman A. Association between mortality and blood pressure variability in hypertensive and normotensive elders: a cohort study. J Clin Hypertens (Greenwich) 2017; 19:753–756.
Mallamaci F, Tripepi G, D’Arrigo G, Borrelli S, Garofalo C, Stanzione G, et al. Blood pressure variability, mortality, and cardiovascular outcomes in CKD patients. Clin J Am Soc Nephrol 2019; 14:233–240.
Yokota K, Fukuda M, Matsui Y, Hoshide S, Shimada K, Kario K. Impact of visit-to-visit variability of blood pressure on deterioration of renal function in patients with nondiabetic chronic kidney disease. Hypertens Res 2013; 36:151–157.
Yano Y, Fujimoto S, Kramer H, Sato Y, Konta T, Iseki K, et al. Long-term blood pressure variability, new-onset diabetes mellitus, and new-onset chronic kidney disease in the Japanese general population. Hypertension 2015; 66:30–36.
Silacci P, Desgeorges A, Mazzolai L, Chambaz C, Hayoz D. Flow pulsatility is a critical determinant of oxidative stress in endothelial cells. Hypertension 2001; 38:1162–1166.
Chappell DC, Varner SE, Nerem RM, Medford RM, Alexander RW. Oscillatory shear stress stimulates adhesion molecule expression in cultured human endothelium. Circ Res 1998; 82:532–539.
Faramawi MF, Delongchamp R, Said Q, Jadhav S, Abouelenien S. Metabolic syndrome is associated with visit-to-visit systolic blood pressure variability in the US adults. Hypertens Res 2014; 37:875–879.
Sohn MW, Epstein N, Huang ES, Huo Z, Emanuele N, Stukenborg G, et al. Visit-to-visit systolic blood pressure variability and microvascular complications among patients with diabetes. J Diabetes Complications 2017; 31:195–220.
Maseli A, Aeschbacher S, Schoen T, Fischer A, Jung M, Risch M, et al. Healthy lifestyle and blood pressure variability in young adults. Am J Hypertens 2017; 30:690–699.
Parati G, Ochoa JE, Lombardi C, Bilo G. Blood pressure variability: assessment, predictive value, and potential as a therapeutic target. Curr Hypertens Rep 2015; 17:537.